If they thought the drug had real value they would have partnered it. They passed so any reasonable person can only conclude one thing. IDX184 was their big hope last year and their lead drug - it speaks volumes when an "insider" says "I think we'll pass" - you can not put a positive spin on it. They have all the inside data and know what's going on and THEY don't want it. Do you think another company will feel comfortable partnering it? Would you if your job/reputation was on the line and you partnered it and it failed? Your boss would fire your ass and say why would you pay $$$ for it when NVS (who is an insider) said they wouldnt touch it.
All of IDIX seemed to be riding on IDX184 - and that now has a lot of doubt cast over it because of NVS. As far as their other drugs IDX102 is still preclinical and their other compunds IDX316 IDX136 and IDX375 are even earlier stage development.
Market Data 
Markets 
AI
